We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
+37.47%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$343M
AUM Growth
+$44.3M
(+15%)
Cap. Flow
-$16.9M
Cap. Flow
% of AUM
-4.94%
Top 10 Holdings %
Top 10 Hldgs %
36.95%
Holding
100
New
31
Increased
17
Reduced
28
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SOLY
Soliton, Inc.
SOLY
|
+$10.1M |
| 2 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$9.42M |
| 3 |
SPDR Gold Trust
GLD
|
+$9.03M |
| 4 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$7.85M |
| 5 |
Cencora
COR
|
+$7.79M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$21.5M |
| 2 |
Envista
NVST
|
+$12.8M |
| 3 |
Boston Scientific
BSX
|
+$10.2M |
| 4 |
AGN
Allergan plc
AGN
|
+$9.74M |
| 5 |
Biogen
BIIB
|
+$8.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.03% |
| 2 | Industrials | 2.48% |
| 3 | Financials | 0.92% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Inogen
INGN
$185M
| $1.92M | 0.56% |
+54,000
| New | +$2.28M |
|
52
Dyadic International
DYAI
$41.2M
| $1.81M | 0.53% |
209,064
+29,269
| +16% | +$195K |
|
53
Vanda Pharmaceuticals
VNDA
$323M
| $1.65M | 0.48% |
144,114
-577,079
| -80% | -$6.53M |
|
|
NBSE
54
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $1.57M | 0.46% |
+8,970
| New | +$1.5M |
|
55
Precision BioSciences
DTIL
$187M
| $1.54M | 0.45% |
+6,168
| New | +$1.35M |
|
56
Anika Therapeutics
ANIK
$261M
| $1.36M | 0.4% |
+36,032
| New | +$1.19M |
|
57
Harrow
HROW
$1.47B
| $1.24M | 0.36% |
238,623
-73,017
| -23% | -$359K |
|
|
MORF
58
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $1.23M | 0.36% |
45,386
-4,300
| -9% | -$80.5K |
|
59
Gyre Therapeutics
GYRE
$688M
| $1.17M | 0.34% |
26,495
-2,667
| -9% | -$125K |
|
|
AYLA
60
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
| $1.16M | 0.34% |
+114,546
| New | +$1.59M |
|
61
Sutro Biopharma
STRO
$427M
| $1.15M | 0.34% |
+14,840
| New | +$1.42M |
|
62
Kodiak Sciences
KOD
$2.62B
| $1.11M | 0.33% |
20,595
+5,595
| +37% | +$316K |
|
63
Progyny
PGNY
$2.47B
| $1.01M | 0.3% |
39,310
-3,790
| -9% | -$87K |
|
64
PUT
Minerva Neurosciences
NERV
$191M
| $878K | 0.26% |
+30,413
| New | +$1.78M |
|
|
ARAV
65
DELISTED
Aravive, Inc. Common Stock
ARAV
| $796K | 0.23% |
68,373
-8,141
| -11% | -$96.6K |
|
66
Bionano Genomics
BNGO
$12.9M
| $789K | 0.23% |
+2,577
| New | +$647K |
|
67
IDEAYA Biosciences
IDYA
$3.51B
| $782K | 0.23% |
+55,000
| New | +$433K |
|
|
TRIL
68
DELISTED
Trillium Therapeutics Inc.
TRIL
| $702K | 0.2% |
86,757
-330,820
| -79% | -$2.05M |
|
69
Kura Oncology
KURA
$855M
| $696K | 0.2% |
+42,683
| New | +$616K |
|
70
Neurogene
NGNE
$683M
| $636K | 0.19% |
1,916
-2,493
| -57% | -$650K |
|
|
BCEL
71
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $458K | 0.13% |
21,523
-25,729
| -54% | -$455K |
|
|
RAPT
72
DELISTED
RAPT Therapeutics
RAPT
| $415K | 0.12% |
1,787
| – | – |
|
|
KDMN
73
DELISTED
Kadmon Holdings, Inc.
KDMN
| $269K | 0.08% |
52,500
-285,000
| -84% | -$1.28M |
|
74
PUT
Seres Therapeutics
MCRB
$51.6M
| $264K | 0.08% |
+2,775
| New | +$243K |
|
75
Cellectar Biosciences
CLRB
$20.7M
| $243K | 0.07% |
+632
| New | +$265K |
|
Similar funds
GUB
KLI
JA
WIC
AAM
TCM
CA
SAM
Sio Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Sio Capital Management held 100 positions worth $343M, up 15% from $298M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Sio Capital Management withdrew a net $16.9M in Q2 2020, closing 22 positions and reducing 28 holdings. Its most notable exit was Amgen, an estimated $21.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 84% a quarter earlier, followed by Industrials and Financials.
Against the trend, Sio Capital Management opened a new position in Soliton, Inc. worth $7.97M.
- Sio Capital Management's largest Q2 2020 buy was Soliton, Inc.: 1,025,000 shares worth $7.97M.
- Sio Capital Management added most to SPDR Gold Trust in Q2 2020, an estimated $9.03M increase.
- Sio Capital Management's biggest Q2 2020 reduction was Boston Scientific, cutting an estimated $10.2M.
- Sio Capital Management fully exited Amgen in Q2 2020, selling an estimated $21.5M.
- Sio Capital Management's ten largest holdings make up 37% of its $343M portfolio in Q2 2020.
- Sio Capital Management opened 31 new positions and closed 22 in Q2 2020.
- Sio Capital Management's portfolio value rose 15% quarter-over-quarter to $343M.
Based on Sio Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.